Dr. Rickard is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-4996Fax+1 919-843-5515- Is this information wrong?
Education & Training
- University of Nebraska Medical Center College of MedicineFellowship, Pulmonary Disease and Critical Care Medicine, 1986 - 1989
- Ohio State University HospitalResidency, Internal Medicine, 1983 - 1986
- Drexel University College of MedicineClass of 1983
Certifications & Licensure
- NC State Medical License 1994 - 2019
- American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 9 citationsA Dose-Ranging Study of the Novel Inhaled Dual PDE 3 and 4 Inhibitor Ensifentrine in Patients with COPD Receiving Maintenance Tiotropium Therapy.Gary T. Ferguson, Edward Kerwin, Tara Rheault, Thomas Bengtsson, Kathleen Rickard> ;International Journal of Chronic Obstructive Pulmonary Disease. 2021 Apr 22
- 5 citationsSymptom Improvement Following Treatment with the Inhaled Dual Phosphodiesterase 3 and 4 Inhibitor Ensifentrine in Patients with Moderate to Severe COPD - A Detailed An...Henrik Watz, Kathleen Rickard, Tara Renae Rheault, Thomas Bengtsson, Dave Singh> ;International Journal of Chronic Obstructive Pulmonary Disease. 2020 Sep 16
- 2 citationsMeasurement of FeNO with a portable, electrochemical analyzer using a 6-second exhalation time in 7-10-year-old children with asthma: comparison to a 10-second exhalat...Kathleen A. Rickard, Neal Jain, Margot MacDonald-Berko> ;The Journal of Asthma. 2019 Dec 1
- Join now to see all
Press Mentions
- Verona Pharma to Present Phase 2 Symptom Data with Ensifentrine in COPD at CHEST 2019October 15th, 2019
- Verona Pharma Strengthens Its Clinical Team Ahead of Phase 3 Development of EnsifentrineJune 24th, 2019
- Verona Pharma plc:Operational Update and Financial Results for the Three and Six Months Ended June30, 2019March 31st, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: